Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats

Ekaterina A. Lesovaya; Kirill I. Kirsanov; Elena E. Antoshina; Lubov S. Trukhanova; Tatiana G. Gorkova; Elena V. Shipaeva; Ramiz M. Salimov; Gennady A. Belitsky; Mikhail V. Blagosklonny; Marianna G. Yakubovskaya; Olga B. Chernova

doi:10.18632/oncotarget.3929

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers: Gerotarget (Focus on Aging):

Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats

Ekaterina A. Lesovaya, Kirill I. Kirsanov, Elena E. Antoshina, Lubov S. Trukhanova, Tatiana G. Gorkova, Elena V. Shipaeva, Ramiz M. Salimov, Gennady A. Belitsky, Mikhail V. Blagosklonny, Marianna G. Yakubovskaya and Olga B. Chernova _

PDF | HTML | How to cite

Oncotarget. 2015; 6:9718-9727. https://doi.org/10.18632/oncotarget.3929

Metrics: PDF 2824 views | HTML 3427 views | ?

Abstract

Ekaterina A. Lesovaya1,*, Kirill I. Kirsanov1,*, Elena E. Antoshina1, Lubov S. Trukhanova1, Tatiana G. Gorkova1, Elena V. Shipaeva2, Ramiz M. Salimov2, Gennady A. Belitsky1, Mikhail V. Blagosklonny3, Marianna G. Yakubovskaya1,** and Olga B. Chernova4,**

1 Department of Chemical Carcinogenesis, Blokhin Cancer Research Center, Moscow, Russia

2 Tartis-Aging LLC, Moscow, Russia

3 Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY, USA

4 Everon Biosciences, Inc., Buffalo, NY, USA

* The first two authors made equal contributions to the study

** The last two authors made equal contributions to the study

Correspondence to:

Marianna Yakubovskaya, email:

Olga B. Chernova, email:

Keywords: gerotarget, aging, benign prostatic hyperplasia, mTOR, rapamycin

Received: December 8, 2014 Accepted: April 15, 2015 Published: April 26, 2015

Abstract

Benign prostatic hyperplasia (BPH) is the most common age-related disease in men. Here we tested the efficacy of Rapatar, a micellar nanoformulation of rapamycin, in two rat models of BPH: testosterone-induced and sulpiride-induced hyperplasia in ventral lobes and lateral/dorsal lobes, respectively. We found that Rapatar prevented hypertrophic and hyperplastic abnormalities and degenerative alterations in both BPH models. Rapatar normalized weight of the lateral lobes in sulpiride-induced BPH, the most relevant animal model of human BPH. Unlike Finasteride, a standard therapy of BPH, Rapatar reduced inflammation caused by sulpiride. No obvious side effects of Rapatar were detected. Our data provide a rationale for clinical trials of Rapatar in patients suffering from BPH.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3929

Publication Alerts

Research Papers: Gerotarget (Focus on Aging):

Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats

Abstract